Cumulative probability of TRM during the first 3 years after transplantation. (A) Patients with hematologic malignancies: Relationship to HLA mismatch (MM) number and direction. The number of patients in each mismatch category known to be alive without relapse at time after transplantation are as follows: 0 MM: day 0, 48; year 1, 28; year 2, 20; year 3, 16; 1 bidirectional MM: day 0, 249; year 1, 81; year 2, 56; year 3, 49; 2 bidirectional MMs: day 0, 414; year 1, 123; year 2, 90; year 3, 76; GVH-O MM: day 0, 35; year 1, 20; year 2, 16; year 3, 3; rejection only MM: day 0, 23; year 1, 4; year 2, 3; year 3, 3. (B) Patients with other diseases: relationship to HLA mismatch (MM) number and direction. The number of patients in each mismatch category known to be alive without relapse at time after transplantation are as follows: 0 MM: day 0, 24; year 1, 22; year 2, 7; year 3, 5; 1 bidirectional MM: day 0, 115; year 1, 54; year 2, 37; year 3, 26; 2 bidirectional MMs: day 0, 112; year 1, 49; year 2, 37; year 3, 28; GVH-O MM: day 0, 23; year 1, 12; year 2, 8; year 3, 6; rejection only MM: day 0, 17; year 1, 6; year 2, 5; year 3, 3. (C) All patients (n = 130) given HLA-matched or GVH-only mismatched CB grafts: relationship to TNC dose × 10⁷/kg. (D) All patients (n = 364) given CB grafts with 1 bidirectional mismatch: relationship to TNC dose × 10⁷/kg.